A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC

Clinical trial NCT06690671 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06690671
Sponsor: Shanghai Chest Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lung Cancer, Non-Small Cell

Start date: 2024-12-15
Primary completion: 2025-06-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.